Press Release

25 06, 2025

Avance Biosciences Launches NGS Center of Excellence in Houston

2025-06-25T14:21:20+00:00

Avance Biosciences has launched a state-of-the-art NGS Center of Excellence in Houston to support biologics and cell and gene therapy development. The facility offers advanced sequencing technologies, GMP- and CLIA-compliant testing, and expert bioinformatics, providing comprehensive support from early research through clinical trials and regulatory submissions...

Avance Biosciences Launches NGS Center of Excellence in Houston2025-06-25T14:21:20+00:00
26 02, 2025

Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities

2025-06-24T13:43:35+00:00

Avance Biosciences™ announces CLIA registration, expanding its high-complexity laboratory testing capabilities for clinical trials, regulatory submissions, and companion diagnostics. This milestone strengthens its commitment to high-quality, regulatory-compliant testing solutions that accelerate drug...

Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities2025-06-24T13:43:35+00:00
2 03, 2023

Avance Biosciences™ licenses SeQure Dx’s GUIDE-seq off-target NGS analysis technology

2025-06-24T13:50:28+00:00

Avance Biosciences™ (Avance), a leading CRO that provides GLP/CGMP-compliant biological testing services that aid drug development and manufacturing, announced today that it has signed a licensing agreement with SeQure Dx, a cutting-edge gene-editing diagnostics company...

Avance Biosciences™ licenses SeQure Dx’s GUIDE-seq off-target NGS analysis technology2025-06-24T13:50:28+00:00
5 05, 2022

Avance Biosciences™ Announces Validation of New Facilities, Expansion of Mammalian Cell Culture and Protein Analysis Services

2025-06-24T13:25:12+00:00

HOUSTON, May 5, 2022 /PRNewswire/ -- Avance Biosciences™, a leading CRO providing GLP/GMP-compliant assay development, assay validation, and sample testing services supporting biological drug development and manufacturing, announced today completion of move-in and validation of an additional 26,000 square feet of laboratory space acquired in the past year. Avance also announced expanded offerings of validated [...]

Avance Biosciences™ Announces Validation of New Facilities, Expansion of Mammalian Cell Culture and Protein Analysis Services2025-06-24T13:25:12+00:00
3 02, 2022

Mission Bio Transfers First Tapestri GMP-Ready CGT Assay to Avance Biosciences™ for Cell-Based Therapies

2025-06-24T14:24:43+00:00

GMP-compliant test for transduction efficiency marks a key milestone for Tapestri’s ability to power single-cell analysis in clinical trial settings for cell & gene therapies SOUTH SAN FRANCISCO, February 2, 2021 -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced today the first tech transfer of a clinical trial-ready cell [...]

Mission Bio Transfers First Tapestri GMP-Ready CGT Assay to Avance Biosciences™ for Cell-Based Therapies2025-06-24T14:24:43+00:00
30 10, 2018

Avance Biosciences™ Completes Successful FDA Inspection

2025-06-24T14:38:19+00:00

HOUSTON, Oct. 30, 2018 - Avance Biosciences™, Inc., a leading biological testing company supporting drug development and manufacturing, announced today that its Houston facility was inspected by the U.S. Food and Drug Administration on October 01 through October 04, 2018.  This inspection focused on the firm’s quality management system, operation procedures, and data integrity, as [...]

Avance Biosciences™ Completes Successful FDA Inspection2025-06-24T14:38:19+00:00
Go to Top